Applied Therapeutics (APLT)
(Real Time Quote from BATS)
$4.36 USD
+0.08 (1.87%)
Updated Apr 29, 2024 01:27 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
APLT 4.36 +0.08(1.87%)
Will APLT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for APLT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APLT
Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why
Bears are Losing Control Over Applied Therapeutics Inc. (APLT), Here's Why It's a 'Buy' Now
APLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase
Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition
Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate
Other News for APLT
Simplify Propel Opportunities ETF: Healthcare Likely To Rise Again In FY24 And Beyond
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
Applied Therapeutics appoints Dale Hooks as CCO
Applied Therapeutics Welcomes Dale Hooks as New CCO
RBC Capital Sticks to Their Buy Rating for Applied Therapeutics (APLT)